
Oncotarget | Everolimus Inhibits Angiogenesis and Lymphangiogenesis in TP53 Mutant HNSCC by Downregulating STAT3/HIF-1α/VEGF Pathway
February 9, 2023
we sought to investigate the mechanism for everolimus-induced inhibition of TP53 HNSCC.” BUFFALO, NY- February 9, 2023 – A new research paper was published in Oncotarget's Volume 14 on February... read more